From: Update on leukotriene receptor antagonists in preschool children wheezing disorders
Author | Pros | Cons | |
---|---|---|---|
Bisgaard[30] | Protection against cold air-induced reactivity | ||
Hakim[22] | Reduced methacoline-induced reactivity | ||
Wheezing (short-term | Straub[31] | Reduced airway resistance and exhaled nitric oxide | |
montelukast monotherapy) | Straub[32] | Improved lung function and symptom score | |
Robertson[33] | Reduced healthcare resource use, symptoms, time-off school/parent work | No effect on hospitalization rate, symptoms duration, β2 or steroids use | |
Szefler[38] | No difference versus budesonide for | Higher rates of exacerbations | |
- time to 1st additional asthma drug at 12 weeks | |||
- time to 1st attack requiring oral steroid | |||
Wheezing (long-term | Kooi[39] | Montelukast versus fluticasone or placebo | |
montelukast | In all groups | In all groups: no differences | |
monotherapy) | - Improved symptoms score | in lung function | |
- Reduced blood eosinophils | |||
Allen-Ramey[41] | Emergency visits fewer versus fluticasone | No differences in hospitalizations or rescue drugs | |
Davies[35] | Similar rates of healthcare resource of cromolyn or ICS | ||
Bisgaard[36] | Lower | ||
- rate of asthma exacerbations | |||
- median time to first exacerbation | |||
- rate of ICS courses | |||
Bacharier[40] | No difference in symptom free-days, oral steroid, healthcare resource use | ||
Wheezing | Johnston | Reduced risk of : | |
(montelukast + ICS) | [44] | - worsened asthma symptoms | |
- unscheduled physician visits |